Blend comparison
KLOW vs GLOW Peptide: Ingredients, KPV and Cost
KLOW adds KPV to the GLOW peptide combination of GHK-Cu, BPC-157 and TB-500. The label examples compared here are GLOW 70 mg and KLOW 80 mg: the KLOW example contains 10 mg of KPV alongside the same amounts of the three shared ingredients.
Jump to a section
GLOW 70 mg vs KLOW 80 mg ingredients
Scroll to compare all columns
| Ingredient | GLOW 70 mg | KLOW 80 mg |
|---|---|---|
| GHK-Cu | 50 mg | 50 mg |
| BPC-157 | 10 mg | 10 mg |
| TB-500 | 10 mg | 10 mg |
| KPV | Not listed | 10 mg |
| Total labeled amount | 70 mg | 80 mg |
These are the per-vial label examples used for the composition calculations below. They describe the compared formulations, rather than every product sold under either name. Label amounts do not establish independently measured content or clinical effects.
- GHK-Cu50 mgin both vials
- BPC-15710 mgin both vials
- TB-50010 mgin both vials
- KPV10 mgin KLOW only
Bar length represents labeled mass. An 80 mg total does not demonstrate a stronger effect.
Basis: the 70 mg GLOW and 80 mg KLOW label examples described above. Bar lengths represent labeled mass.
The extra 10 mg comes entirely from KPV. An 80 mg total does not mean more GHK-Cu, BPC-157 or TB-500, or demonstrate a stronger effect. Neither total specifies an amount to administer.
GLOW vs KLOW ratios: what changes?
In GHK-Cu : BPC-157 : TB-500 order, GLOW has a 5:1:1 mass ratio. Add KPV at the end and KLOW becomes 5:1:1:1. The relationship between the three shared ingredients stays the same.
Their percentages change because the total changes. For example, 50 mg of GHK-Cu is approximately 71.4% of a 70 mg GLOW vial, but 62.5% of an 80 mg KLOW vial. The amount of GHK-Cu remains 50 mg in both. The GLOW ingredient guide explains the individual peptide names and mass shares.
Equal weights of the blends contain different ingredient amounts
Comparing one whole vial of each formula keeps the three shared ingredient amounts equal. Comparing the same total weight of each blend does something different.
Consider an illustrative 70 mg sample of each formula, calculated from the label ratios and assuming uniform blends:
Scroll to compare all columns
| Ingredient | 70 mg of GLOW | 70 mg of KLOW |
|---|---|---|
| GHK-Cu | 50 mg | 43.75 mg |
| BPC-157 | 10 mg | 8.75 mg |
| TB-500 | 10 mg | 8.75 mg |
| KPV | 0 mg | 8.75 mg |
The KLOW sample contains 87.5% as much of each shared ingredient, because 70 ÷ 80 = 0.875. Some of its total weight is KPV.
That matters when interpreting a comparison experiment: an equal-weight design changes both the presence of KPV and the amounts of the other ingredients. It cannot isolate KPV’s contribution. These are composition calculations, not dosing instructions or measures of potency.
What does KPV add to the research?
KPV is a tripeptide, meaning it contains three amino acids: lysine–proline–valine. Its relevance to the comparison comes from studies of intestinal inflammation. Dalmasso and colleagues, 2008
KPV in cells and mouse colitis models
In 2008, Dalmasso’s team studied cultured human intestinal and immune cells, then two mouse models of chemically induced colitis, or colon inflammation. KPV reduced inflammatory signaling in the cells. Supplied in the mice’s drinking water, it also reduced measures of intestinal inflammation. These were cell and animal experiments; the human cells were grown in the laboratory, not treated inside patients. Original KPV study
A modified KPV preparation in a 2026 experiment
A later mouse study compared free KPV with proKPV, a chemically modified form that assembles into nanoparticles for oral delivery. Over seven days, with six mice per group, proKPV reduced weight loss, disease activity scores and colon shortening. Free KPV did not improve those outcomes under the conditions tested. The disease activity score combined weight loss, stool consistency and fecal bleeding. Cheng and colleagues, 2026
That experiment tested particular KPV preparations and delivery conditions. Its results cannot be assigned to the four-ingredient KLOW blend.
Has KLOW been shown to work better than GLOW?
The studies above do not establish that KLOW works better than GLOW. Neither compares the complete blends. To test an advantage from adding KPV, researchers would need to keep the shared ingredients comparable and measure the claimed outcome.
Mouse colitis findings cannot establish better digestion, skin texture or injury recovery in people. The GLOW peptide benefits guide examines the shared ingredients’ skin and recovery findings separately. These KPV studies also cannot rank the blends by human side-effect rates; the GLOW side effects guide covers the available safety observations.
How should cost fit into the comparison?
Price is a purchasing detail, separate from evidence that a blend works better. Compare the exact formulation, batch documentation and complete order total for a research project.
The GLOW buying guide keeps current product and ordering information together. The studies above address specific KPV preparations; they do not compare commercial GLOW and KLOW products.
Sources for
this article.
Original studies and public guidance cited in this article.
- 01
Dalmasso et al.: KPV transport and intestinal inflammation
Gastroenterology · 2008 · Cell and mouse experiments
- 02
Cheng and colleagues' study
PubMed Central / U.S. National Library of Medicine · Original paper
- 03
Metric and SI prefixes
National Institute of Standards and Technology · Units and conversions
